129 related articles for article (PubMed ID: 21434838)
1. Lysophosphatidic acid-1-receptor targeting agents for fibrosis.
Rancoule C; Pradère JP; Gonzalez J; Klein J; Valet P; Bascands JL; Schanstra JP; Saulnier-Blache JS
Expert Opin Investig Drugs; 2011 May; 20(5):657-67. PubMed ID: 21434838
[TBL] [Abstract][Full Text] [Related]
2. Pro-fibrotic activity of lysophosphatidic acid in adipose tissue: in vivo and in vitro evidence.
Rancoule C; Viaud M; Gres S; Viguerie N; Decaunes P; Bouloumié A; Langin D; Bascands JL; Valet P; Saulnier-Blache JS
Biochim Biophys Acta; 2014 Jan; 1841(1):88-96. PubMed ID: 24120919
[TBL] [Abstract][Full Text] [Related]
3. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.
Budd DC; Qian Y
Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox.
Llona-Minguez S; Ghassemian A; Helleday T
Prog Lipid Res; 2015 Apr; 58():51-75. PubMed ID: 25704399
[TBL] [Abstract][Full Text] [Related]
5. Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis.
Rancoule C; Dusaulcy R; Tréguer K; Grès S; Attané C; Saulnier-Blache JS
Biochimie; 2014 Jan; 96():140-3. PubMed ID: 23639740
[TBL] [Abstract][Full Text] [Related]
6. Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials.
Lin YH; Lin YC; Chen CC
Cells; 2021 Jun; 10(7):. PubMed ID: 34209775
[TBL] [Abstract][Full Text] [Related]
7. First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor.
Im DS
Arch Pharm Res; 2012 Jun; 35(6):945-8. PubMed ID: 22870802
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel non-carboxylic acid 5-amino-4-cyanopyrazole derivatives as potent and highly selective LPA1R antagonists.
Sidduri A; Budd DC; Fuentes ME; Lambros T; Ren Y; Roongta V; Schoenfeld RC; Gillespie P; Stevenson CS; Truitt T; Qian Y
Bioorg Med Chem Lett; 2014 Sep; 24(18):4450-4454. PubMed ID: 25155385
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays.
Willier S; Butt E; Grunewald TG
Biol Cell; 2013 Aug; 105(8):317-33. PubMed ID: 23611148
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid and renal fibrosis.
Pradère JP; Gonzalez J; Klein J; Valet P; Grès S; Salant D; Bascands JL; Saulnier-Blache JS; Schanstra JP
Biochim Biophys Acta; 2008 Sep; 1781(9):582-7. PubMed ID: 18455518
[TBL] [Abstract][Full Text] [Related]
11. LPA1 receptor activation promotes renal interstitial fibrosis.
Pradère JP; Klein J; Grès S; Guigné C; Neau E; Valet P; Calise D; Chun J; Bascands JL; Saulnier-Blache JS; Schanstra JP
J Am Soc Nephrol; 2007 Dec; 18(12):3110-8. PubMed ID: 18003779
[TBL] [Abstract][Full Text] [Related]
12. Regulation of silicosis formation by lysophosphatidic acid and its receptors.
Cong C; Mao L; Zhang Y; Zhao Z; Xu X; Zhao J
Exp Lung Res; 2014 Sep; 40(7):317-26. PubMed ID: 24926730
[TBL] [Abstract][Full Text] [Related]
13. Lipids and eicosanoids in fibrosis: emerging targets for therapy.
Castelino FV
Curr Opin Rheumatol; 2012 Nov; 24(6):649-55. PubMed ID: 22810365
[TBL] [Abstract][Full Text] [Related]
14. Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells.
Ren Y; Guo L; Tang X; Apparsundaram S; Kitson C; Deguzman J; Fuentes ME; Coyle L; Majmudar R; Allard J; Truitt T; Hamid R; Chen Y; Qian Y; Budd DC
Microvasc Res; 2013 Jan; 85():59-67. PubMed ID: 23084965
[TBL] [Abstract][Full Text] [Related]
15. Design of anticancer lysophosphatidic acid agonists and antagonists.
Parrill AL
Future Med Chem; 2014 May; 6(8):871-83. PubMed ID: 24962280
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic Acid Signaling in Diabetic Nephropathy.
Lee JH; Kim D; Oh YS; Jun HS
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212704
[TBL] [Abstract][Full Text] [Related]
17. The development of modulators for lysophosphatidic acid receptors: A comprehensive review.
Liu W; Hopkins AM; Hou J
Bioorg Chem; 2021 Dec; 117():105386. PubMed ID: 34695732
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic Acid signals through specific lysophosphatidic Acid receptor subtypes to control key regenerative responses of human gingival and periodontal ligament fibroblasts.
George J; Headen KV; Ogunleye AO; Perry GA; Wilwerding TM; Parrish LC; McVaney TP; Mattson JS; Cerutis DR
J Periodontol; 2009 Aug; 80(8):1338-47. PubMed ID: 19656035
[TBL] [Abstract][Full Text] [Related]
19. LPA(3), a unique G protein-coupled receptor for lysophosphatidic acid.
Hama K; Aoki J
Prog Lipid Res; 2010 Oct; 49(4):335-42. PubMed ID: 20230855
[TBL] [Abstract][Full Text] [Related]
20. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
Okudaira S; Yukiura H; Aoki J
Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
